The WFH Humanitarian Aid Program aims to improve the lack of access to care and treatment for people with inherited bleeding disorders in developing countries, and is a critically important endeavour for the bleeding disorders community. Today, the World Federation of Hemophilia (WFH) is proud to announce that Grifols will extend its commitment to the WFH Humanitarian Aid Program until 2030.
Grifols will donate a minimum of 240 million IUs of blood clotting factor medicines (Factor VIII and Factor IX) to the WFH Humanitarian Aid Program over the next eight years, from 2022 to 2030. This contribution extends the company’s commitment that began in 2014 and will bring its total commitment to more than 440M IU of Factor VIII over 16 years.
For more than two decades, Grifols has been a proud supporter of the WFH and its efforts to improve access to treatment of bleeding disorders around the world. The extended partnership with WFH reaffirms the commitment of Grifols to the global hemophilia community and represents the company’s most significant contribution to the WFH Humanitarian Aid Program to date.
“Helping to address global health inequities is an essential part of fulfilling our corporate mission,” says Victor Grifols Deu, co-CEO of Grifols. “We consider product donations to the World Federation of Hemophilia to be an ethical imperative for our company rather than a simple choice,” add Raimon Grifols, co-CEO of Grifols.
“Since its creation in 1996, the WFH Humanitarian Aid Program has benefitted almost 100,000 people in over 100 countries. When patients are able to receive consistent and reliable access to treatment and care, they have hope for a better quality of life,” said Alain Baumann, CEO of WFH.
About the WFH Humanitarian Aid Program
The WFH Humanitarian Aid Program improves the lack of access to care and treatment by providing much-needed support for people with inherited bleeding disorders in developing countries. By providing patients with a more predictable and sustainable flow of humanitarian aid donations, the WFH Humanitarian Aid Program makes it possible for patients to receive consistent and reliable access to treatment and care. None of this would be possible without the generous support of Sanofi Genzyme and Sobi, our Founding Visionary Contributors; Bayer and Roche, our Visionary Contributors; Grifols, our Leadership Contributor; and our Contributors, CSL Behring and Takeda. To learn more about the WFH Humanitarian Aid Program, visit www.treatmentforall.org.